Dengue type 4 live-attenuated vaccine viruses passaged in Vero cells affect genetic stability and dengue-induced hemorrhaging in mice

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Lee, Hsiang Chi ^a   Yen, Yu Ting ^c   Chen, Wen Yu ^c   Wu Hsieh, Betty A ^c   Wu, Suh Chin ^a,b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DENGUE VACCINE; LIVE VACCINE; RNA POLYMERASE; AMINO ACID; MUTANT PROTEIN; NUCLEOTIDE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING; CELL STRAIN; CELL STRAIN MRC 5; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 4; DISEASE SEVERITY; ERROR; GENE DELETION; GENE REPLICATION; GENE SEQUENCE; GENETIC STABILITY; HUMAN; HUMAN CELL; MOUSE; NEWBORN; NONHUMAN; POINT MUTATION; VERO CELL; VIRUS GENOME; VIRUS LOAD; VIRUS MUTANT; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; C57BL MOUSE; CERCOPITHECUS; DENGUE VIRUS; GENETICS; IMMUNOCOMPETENCE; IMMUNOLOGY; METABOLISM; MUTATION; PATHOGENICITY; VIROLOGY; VIRULENCE; VIRUS CULTURE; VIRUS GENE;

DENGUE VIRUS; MUS;

AMINO ACIDS; ANIMALS; ANIMALS, NEWBORN; CERCOPITHECUS AETHIOPS; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; GENES, VIRAL; HEMORRHAGE; HUMANS; IMMUNOCOMPETENCE; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; MUTATION; NUCLEOTIDES; SERIAL PASSAGE; VACCINES, ATTENUATED; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRULENCE;

EID: 80055040647     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025800     Document Type: Article

References (48)

1. Lambrechts L, Scott TW, Gubler DJ, (2010) Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis 4: e646.
2. Paranjape SM, Harris E, (2010) Control of Dengue Virus Translation and Replication. Curr Top Microbiol 338: 15-34.
3. Gubler DJ, (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10: 100-103.
4. Gubler DJ, (2002) The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 33: 330-342.
5. Halstead SB, (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239: 476-481.
6. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders RJ, et al. (1998) Dengue and dengue haemorrhagic fever. Lancet 352: 971-977.
7. Webster DP, Farrar J, Rowland-Jones S, (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9: 678-687.
8. Halstead SB, Heinz FX, Barrett ADT, Roehrig JT, (2005) Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine 23: 849-856.
9. Halstead SB, (2008) Dengue virus-mosquito interactions. Annu Rev Entomol 53: 273-291.
10. Bhamarapravati N, Sutee Y, (2000) Live attenuated tetravalent dengue vaccine. Vaccine 18: 44-47.
11. Durbin AP, Whitehead SS, (2010) Dengue Vaccine Candidates in Development. Curr Top Microbiol 338: 129-143.
12. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, et al. (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69: 48-60.
13. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, et al. (2004) Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23: 99-109.
14. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, et al. (2002) Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66: 264-272.
15. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
16. Kanesa-Thasan N, Edelman R, Tacket CO, WassermanSS, Vaughn DW, et al. (2003) Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 69: 17-23.
17. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, et al. (2003) Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69: 24-31.
18. Aunins JG, (2000) Viral vaccine production in cell culture. In: Spier RE, editor. Encyclopedia of Cell Technology John Wiley & Sons 2: 1182-1217.
19. Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, et al. (2001) Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75: 934-942.
20. Chambers TJ, Nestorowicz A, Mason PW, Rice CM, (1999) Yellow fever Japanese encephalitis chimeric viruses: Construction and biological properties. J Virol 73: 3095-3101.
21. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, et al. (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405-413.
22. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, et al. (2001) Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75: 7290-7304.
23. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, et al. (2002) Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298: 146-159.
24. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, et al. (2004) Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78: 4761-4775.
25. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, et al. (2000) Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477-5485.
26. Huang CYH, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, et al. (2003) Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77: 11436-11447.
27. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, et al. (1997) Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230: 300-308.
28. Lai CJ, Bray M, Men R, Cahour A, Chen W, et al. (1998) Evaluation of molecular strategies to develop a live dengue vaccine. Clin Diagn Virol 10: 173-179.
29. Lai CJ, Zhao BT, Hori H, Bray M, (1991) Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci USA 88: 5139-5143.
30. Men R, Bray M, Clark D, Chanock RM, Lai CJ, (1996) Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 70: 3930-3937.
31. Blaney JEJ, Johnson DH, Manipon GG, Firestone CY, Hanson CT, et al. (2002) Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300: 125-139.
32. Blaney JE, Manipon GG, Firestone CY, Johnson DH, et al. (2003) Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 21: 4317-4327.
33. Stinchcomb DT, Kinney RM, Huang CY, Wiggan O, Kalanidhi AP, et al. (2007) Development of dengue 2-PDK-53-based chimeric tetravalent dengue vaccines. Third Asian Regional Dengue Research Network Meeting, Taipei, Taiwan.
34. Liu CC, Lee SC, Butler M, Wu SC, (2008) High genetic stability of dengue virus propagated in MRC-5 cells as compared to the virus propagated in vero cells. PLoS ONE 3: e1810.
35. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JEJ, et al. (2005) rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191: 710-718.
36. Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA, (2007) Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol 81: 5518-5526.
37. Wu-Hsieh BA, Yen YT, Chen HC, (2009) Dengue hemorrhage in a mouse model. Ann N Y Acad Sci 1171 (Suppl 1): E42-47.
38. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, et al. (2004) High fidelity of yellow fever virus RNA polymerase. J Virol 78: 1032-1038.
39. Trent D, (2010) WHO working group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. Vaccine doi:10.1016/j.vaccine.2010.10.043.
40. Chambers TJ, Droll DA, Tang Y, Liang Y, Ganesh VK, et al. (2005) Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities. J Gen Virol 86: 1403-1413.
41. Chambers TJ, Grakoui A, Rice CM, (1991) Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol 65: 6042-6050.
42. Chandramouli S, Joseph JS, Daudenarde S, Gatchalian J, Cornillez-Ty C, et al. (2010) Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol 84: 3059-3067.
43. Falgout B, Pethel M, Zhang YM, Lai CJ, (1991) Both Nonstructural Proteins Ns2b and Ns3 Are Required for the Proteolytic Processing of Dengue Virus Nonstructural Proteins. J Virol 65: 2467-2475.
44. Yusof R, Clum S, Wetzel M, Murthy HMK, Padmanabhan R, (2000) Purified NS2B/NS3 Serine Protease of Dengue Virus Type 2 Exhibits Cofactor NS2B Dependence for Cleavage of Substrates with Dibasic Amino Acids in Vitro. J Biol Chem 275: 9963-9969.
45. Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, et al. (2006) Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 13: 372-373.
46. Brinworth RI, Fairlie DP, Leung DL, Young PR, (1999) Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor. J Gen Virol 80: 1167-1177.
47. Droll DA, Krishna Murthy HM, Chambers TJ, (2000) Yellow fever virus NS2B-NS3 protease: charge-to-alanine mutagenesis and deletion analysis define regions important for protease complex formation and function. Virology 275: 335-347.
48. Huang CYH, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, et al. (2000) Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74: 3020-3028.